Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biocorrx Inc - SIC # 8361 - RESIDENTIAL CARE
Ticker
Exchange
SIC #
Website
Latest Ticker
BICX
Over the counter
8361
https://www.biocorrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biocorrx Inc
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
- Apr 3rd, 2024 12:30 pm
BioCorRx Reports Business Update for 2023
- Apr 2nd, 2024 12:30 pm
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
- Feb 28th, 2024 3:52 pm
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
- Feb 8th, 2024 2:58 pm
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
- Jan 9th, 2024 1:30 pm
BioCorRx Reports Business Update for the Third Quarter of 2023
- Nov 14th, 2023 5:52 pm
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
- Aug 15th, 2023 1:00 pm
BioCorRx Reports Business Update for the Second Quarter of 2023
- Aug 14th, 2023 8:34 pm
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
- Jul 18th, 2023 12:30 pm
BioCorRx Provides Business Update for the First Quarter of 2023
- May 16th, 2023 12:30 pm
Scroll